《大行》里昂降科伦博泰生物(06990.HK)目标价至500.7元 评级“跑赢大市”

阿斯达克财经
Yesterday

里昂发表研究报告指,科伦博泰生物(06990.HK) 去年收入按年升6.5%至20.58亿元人民币,净亏损按年扩大43.2%至3.82亿元人民币,均胜于预期,主要受合作收入强于预期所带动。该行指,2025年下半年产品销售(不包括与国家医保药品目录相关的价格调整)按半年增长。管理层预计,sac-TMT在纳入国家医保药品目录后的销售额将在今年翻倍,而公司将于今年披露更多sac-TMT一线非小细胞肺癌(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10